Iclusig Approved for Rare Leukemias
FRIDAY, Dec. 14 (HealthDay News) -- Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia -- cancers of the blood and bone marrow.
The drug was sanctioned for adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), the FDA said Friday in a news release.
Iclusig blocks the effects of proteins that promote development of cancer cells, the agency said. The drug was granted accelerated approval following a single study of 449 people with either CML or Ph+ ALL.
The product's label will include a boxed warning that users are at heightened risk of blood clots and liver poisoning. More common but less serious clinical side effects included high blood pressure, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain and nausea.
Iclusig is marketed by Ariad Pharmaceuticals, based in Cambridge, Mass.
The FDA has more about this approval.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
Glossary of Leukemia TermsView All Terms
Leukemia Related Links from WrongDiagnosis
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Down Syndrome
- Epstein-Barr Virus
- Fanconi's Syndrome
We'd like your feedback.
Are you a cancer patient, cancer survivor or a caregiver for a cancer patient? Please complete a very brief survey to improve patient care.
A survey will be presented to you after you finish viewing our Leukemia content.
Take a Personalized Health Test
Leukemia Related Conditions
Health News TodayFeed
- Experimental Drug May Boost Leukemia Survival, Without Chemo03/12/2014
- Gene Variations Leave Infants at Risk of Leukemia, Study Suggests02/19/2014
- Experimental Therapy Shows Promise Against Type of Adult Leukemia02/19/2014
- Imbruvica Approval Expanded to Include Chronic Leukemia02/12/2014
- Body's Immune System Destroys Would-Be Cancer Cells Daily: Study02/03/2014
- View More Leukemia News